Study Evaluating MST-997 in Advanced Malignant Solid Tumors

A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00277836

Enrollment

Registered

2006-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2006-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

malignant tumor

Brief summary

MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.

Interventions

DRUGMST-997

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diagnosis of malignant solid tumor with measurable disease * Life expectancy of at least 12 weeks * ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2

Exclusion criteria

* Recent major surgery, radiation therapy or anti-cancer treatment * History of any other prior malignancy within last 5 years

Design outcomes

Primary

Measure	Time frame
To evaluate the safety, tolerability and MTD (maximum tolerated dose) of MST-997.	—

Secondary

Measure	Time frame
Preliminary pharmacokinetic information on the pharmacokinetics (during cycle 1) abd anti-tumor activity (assessed approximately every 8 weeks) of on MST-997	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026